GTCM
KDNY

Gyon Technologies Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Gyon Technologies Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,931
Closed -$496K – 473
2022
Q4 		$496K Buy
+18,931
New +$419K 0.19% 146

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Gyon Technologies Capital Management's KDNY Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 18,931 shares — an estimated $496K sold.

Gyon Technologies Capital Management first reported a position in KDNY in Q4 2022 and held it in 1 quarter. The position peaked at $496K in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 18,931 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $496K.
  • Gyon Technologies Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $496K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.